CVRX (CVRX) Stock Analysis
Verdict: AVOID
High 86.9% gross margins show strong product unit economics, but a $40.8M annual cash burn creates heavy equity dilution risk.
Investment score: 36/100
Is CVRX Stock Worth Reviewing? AI Model Thesis
CVRx trades at a low P/S of 1.17x with gross margins of 86.92%, but negative operating cash flow (-$40.17M in 2025) and deceleration in revenue growth present substantial dilution risk.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| STEX | -0.07 | 0.87 | 499.43 | -0.14 | — | -3430.38 |
| GUTS | -0.44 | -46.27 | 0.00 | -0.87 | — | 0.00 |
| VANI | -3.54 | 5.69 | 0.00 | -3.89 | — | 0.00 |
| RTGN | -36.04 | -28.42 | 0.00 | 218.27 | — | 0.00 |
| MYO | -4.73 | 11.79 | 1.44 | -6.24 | — | -0.34 |
Should You Buy or Sell CVRX Stock? Model Reasoning
Despite outstanding gross margins of 86.92% and $75.71M in cash reserves (~22 months of runway), CVRx generated an operating loss of -$51.27M and an FCF burn of -$40.75M in 2025 while revenue growth slowed to 11.96% YoY. The model views equity dilution as highly probable before the company reaches cash-flow breakeven.
CVRX Fair Value & Price Target — AI Valuation
- Model Assumptions: ["Annual cash burn stabilizes near -$38M to -$40M, preserving ~22 months of cash runway ($75.7M cash as of Q4 2025).","Revenue grows at 12-15% annually, reaching $63M-$68M over the next 12-18 months.","Gross margin remains industry-leading at 85%+ (86.9% in FY2025)."]
CVRX Risk & Opportunity Analysis
Key Investment Risks
- Severe Equity Dilution Risk from Persistent Cash Burn — Free cash flow was -$40.75M in 2025 and -$40.51M in 2024; without cash positivity by late 2027, the company will likely need to issue equity at depressed prices.
- Commercial Expansion Deceleration — Revenue growth moderated to 11.96% in 2025 ($56.65M vs $51.29M in 2024), down from 30.5% growth in 2024, signaling potential sales execution headwinds.
- Heavy Loss Profile and Accumulated Debt Burden — Operating losses reached -$51.27M in 2025 against $50.79M in total debt, creating long-term balance sheet fragility if debt refinancing becomes necessary.
- Wall Street Sentiment Downgrades — Analyst sentiment has soured with downgrades from Lake Street (Hold in August 2026) and JP Morgan (Underweight), which may continue to suppress valuation multiples.
Growth Opportunities & Upside Drivers
- High Unit Profitability with 86.92% Gross Margin — Gross margin expanded to 86.92% in 2025 (up from 83.9% in 2023), proving strong manufacturing performance and pricing leverage for the Barostim system.
- Near-Term Liquidity Runway of ~22 Months — Cash and cash equivalents stood at $75.71M as of December 31, 2025, offering roughly 22 months of operational buffer against 2025 FCF burn of -$40.75M.
- Large Addressable Market in Heart Failure — Analyst consensus models revenue expanding from $56.65M in 2025 to $110.0M by 2029, reflecting secular market penetration of neuromodulation therapy.
- Discounted Multiples Relative to Medtech Peers — CVRx trades at a P/S of 1.17x and EV/Sales of 1.09x compared to peer MYO at 1.44x, offering valuation expansion potential if commercial growth re-accelerates.
CVRX Action Plan — Entry, Exit and Stop Loss from the Model View
moderate
aggressive
conservative
Frequently Asked Questions About CVRX (CVRX)
Is CVRX stock a good investment?
The cached TradeMates AI model rates CVRX as AVOID with an investment score of 36/100. CVRx trades at a low P/S of 1.17x with gross margins of 86.92%, but negative operating cash flow (-$40.17M in 2025) and deceleration in revenue growth present substantial dilution risk. This is algorithmic model output, not personal investment advice.
Does CVRX pay a dividend?
The cached stock data on this page does not show a positive dividend yield for CVRX. Dividend status can change, so verify the latest company filings before relying on income assumptions.
What does CVRX stock do?
Commercial-stage medical device manufacturer specializing in neuromodulation systems (Barostim) for patients with heart failure with reduced ejection fraction (HFrEF).
What is CVRX stock's price target?
This cached page does not contain a precise model fair value for CVRX.
Is CVRX stock a buy?
The TradeMates model verdict for CVRX is AVOID with an investment score of 36/100. Treat this as a model signal to review, not a personal buy recommendation.
Is CVRX a good dividend stock?
CVRX is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.